Sionna Therapeutics (NASDAQ:SION) Cut to “Neutral” at BTIG Research

Sionna Therapeutics (NASDAQ:SION) was downgraded by equities researchers at BTIG Research from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Monday.

Several other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Stifel Nicolaus restated a “hold” rating and set a $7.00 price target on shares of Sionna Therapeutics in a research report on Monday. Guggenheim restated a “neutral” rating on shares of Sionna Therapeutics in a research note on Monday. JonesTrading raised their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Finally, Royal Bank Of Canada upgraded Sionna Therapeutics from an “underperform” rating to a “sector perform” rating and set a $5.00 price target for the company in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $42.22.

Sionna Therapeutics Stock Performance

Shares of NASDAQ SION traded down $46.38 during midday trading on Monday, hitting $4.67. 34,579,355 shares of the stock traded hands, compared to its average volume of 623,337. Sionna Therapeutics has a one year low of $4.01 and a one year high of $54.97. The business has a 50 day moving average price of $42.35 and a two-hundred day moving average price of $40.42. The company has a market cap of $210.90 million, a PE ratio of -2.14 and a beta of 1.32.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Thursday, August 6th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.02). As a group, equities research analysts forecast that Sionna Therapeutics will post -2.63 EPS for the current fiscal year.

Insider Activity

In related news, Director Peter A. Thompson sold 115,844 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares of the company’s stock, valued at approximately $116,292,403.50. The trade was a 4.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 115,844 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the sale, the director owned 2,555,877 shares in the company, valued at $116,292,403.50. This represents a 4.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 403,726 shares of company stock valued at $18,259,354. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. State of Wyoming bought a new position in shares of Sionna Therapeutics in the second quarter worth $35,000. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the fourth quarter valued at $36,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Sionna Therapeutics in the 2nd quarter worth about $44,000. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics during the 3rd quarter valued at about $30,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Sionna Therapeutics during the fourth quarter worth about $58,000.

More Sionna Therapeutics News

Here are the key news stories impacting Sionna Therapeutics this week:

• Neutral Sentiment: Several analysts maintained cautious ratings while setting targets above the recent share price. Stifel Nicolaus reaffirmed a “hold” rating with a $7 target, while Wedbush reiterated “neutral” with a $5 target. Royal Bank of Canada upgraded Sionna from “underperform” to “sector perform,” also assigning a $5 target. The Fly analyst ratings
• Neutral Sentiment: Guggenheim reaffirmed its “neutral” rating, indicating that the firm does not currently see a clear catalyst to change its view. The Fly Guggenheim rating
• Negative Sentiment: Raymond James downgraded Sionna from “strong buy” to “market perform,” and Citizens JMP cut its rating from “market outperform” to “market perform.” The downgrades reflect reduced confidence following the clinical update. The Fly analyst downgrades
• Negative Sentiment: Sionna reported topline results from two cystic fibrosis development programs. Its experimental SION-719 therapy reportedly failed to demonstrate sufficiently encouraging results in a mid-stage trial, prompting the company to discontinue the program. The setback removes a key pipeline opportunity and is the primary reason investors are selling the stock. STAT Sionna cystic fibrosis trial report
• Negative Sentiment: The company is refocusing its cystic fibrosis pipeline after the trial setback, increasing uncertainty around its remaining development programs and potential future revenue. TipRanks Sionna trial update
• Negative Sentiment: Johnson Fistel announced an investigation into potential federal securities-law violations related to the sharp market reaction and the company’s disclosures. Although the investigation does not establish wrongdoing, it adds legal and reputational risk. Johnson Fistel investigation announcement

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.